<s> Food and Drug Administration spokesman Jeff Nesbit said the agency has turned over evidence in a criminal investigation concerning Vitarine Pharmaceuticals Inc. to the U.S. Attorney 's office in Baltimore . </s>
<s> Neither Vitarine nor any of the Springfield Gardens , N.Y. , company 's officials or employees have been charged with any crimes . </s>
<s> Vitarine won approval to market a version of a blood pressure medicine but acknowledged that it substituted a SmithKline Beecham PLC product as its own in tests . </s>
<s> Mr. Nesbit also said the FDA has asked Bolar Pharmaceutical Co. to recall at the retail level its urinary tract antibiotic . </s>
<s> But so far the company has n't complied with that request , the spokesman said . </s>
<s> Bolar , the subject of a criminal investigation by the FDA and the Inspector General 's office of the Health and Human Services Department , only agreed to recall two strengths of its version of Macrodantin `` as far down as direct customers , mostly wholesalers , '' Mr. Nesbit said . </s>
<s> Bolar , of Copiague , N.Y. , earlier began a voluntary recall of both its 100 milligram and 50 milligram versions of the drug . </s>
<s> The FDA has said it presented evidence it uncovered to the company indicating that Bolar substituted the brand-name product for its own to gain government approval to sell generic versions of Macrodantin . </s>
<s> Bolar has denied that it switched the brand-name product for its own in such testing . </s>
